StockrabitBrowse analysts
Analyst questions

Bharat Celly

Equirus Securities
2Calls
2Companies
Read latest question
LALPATHLAB

Dr. Lal Path Labs Ltd.

All company calls
Dr. Lal Path Labs Ltd. CC-Mar25.pdf
25 Apr 2025
Open call
  1. Thanks for the opportunity. We have been actually seeing volume growth of around mid-single digit since last almost like 7-8 quarters. And despite the fact that we are moving to the hinterlands of India, can we see these numbers inching up to the high single digit?

    Read in transcript
  2. When we will start seeing this Hinterland started picking up probably Tier-2, Tier-3 towns, will it be a case where our patient volume growth will look higher, but the realizations will start taking a hit considering the prices there will be relatively lower?

    Read in transcript
  3. And according to you how the pricing for the competitors will be in these markets?

    Read in transcript
AJANTPHARM

Ajanta Pharma Limited

All company calls
Ajanta Pharma Limited CC-Sep23.pdf
31 Oct 2023
Open call
  1. So, we have been referring to that there has been some change in the US structurally. So just I was trying to get a sense that how the overall market is shaping up, whether you are seeing that people are ready to pay higher price considering the shortage in the market or the volume growth has been more of leading the growth?

    Read in transcript
  2. When the customer is coming to you, are they asking for a longer duration contract or these are more of a shorter-term contracts till the time new players who are calling new supplies also join in?

    Read in transcript
  3. Sir, actually what we have seen over the past is that whenever there is a shortage , probably six months or nine months down the line, new supplies come in the market. So , are you foreseeing any sort of similar trend to emerge this time or it will be more of a permanent lock which we are referring to?

    Read in transcript
+5 more questions in this call